Clinical trial
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With…
NCT00006016 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006016 |
|---|---|
| Title | Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery |
| Official title | An Evaluation of Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer |
| Intervention type | Drug, Other |
| Interventions | thalidomide, doxorubicin hydrochloride, laboratory biomarker analysis |
| Enrollment | 75 |
| Start date | May 1, 2000 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: